TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This is a phase Ib single-arm, open-label clinical trial determining the feasibility and
efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal
adenocarcinoma. These are subjects who are not candidates for curative treatments and who
have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum
agent.